Triple-Drug attack offers hope for Hard-to-Treat colorectal cancer

NCT ID NCT06497985

Recruiting now Disease control Sponsor: Chipscreen Biosciences, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three drugs (tucidinostat, sintilimab, and bevacizumab) can help people with a specific type of advanced colorectal cancer (MSS/pMMR) who have already tried at least two standard treatments. About 430 adults aged 18 to 75 will be randomly assigned to receive either the triple combination or a single drug (fruquintinib). The main goal is to see if the combination helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Rui-Hua Xu
RECRUITING

Guangzhou, Guangdong, 510050, China

Contact Phone: •••-•••-•••• Email: •••••@•••••